Whether to resume immune checkpoint inhibitor therapy (ICI) after discontinuation is controversial because of the unclear safety, efficacy, and survival be
Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.
Amma Asare, MD, PhD, discusses the elevated risk of therapy-related myeloid neoplasms or secondary leukemias in gynecologic cancers after a PARP inhibitor.
Earlier use of liso-cel may improve responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Tusamitamab ravtansine vs docetaxel was not significantly different regarding survival in patients with advanced nonsquamous non–small cell lung cancer.
Zanidatamab is a HER2-targeted bispecific antibody that binds to two non-overlapping HER2 domains and crosslinks neighboring HER2 proteins. In the primary analysis of the phase…
An abstract is unavailable.
Over the last 10 years, numerous studies have profiled human tumors by single-cell RNA-seq. In this perspective, Tirosh and Suva describe the cell states most…
AbstractBackground. To address the need for treatments for patients with COVID-19, three therapies have been given either full approval or Emergency Use Au
This cross-sectional study estimates the prevalence of financial hardship among cancer survivors and investigates its associations with individual- and community-level characteristics.
Annals of Surgical Oncology – Liver resection (LR) and radiofrequency ablation (RFA) are curative-intent therapies for early stages of hepatocellular carcinoma (HCC). If HCC recurs,…
